Eiger Bio to Participate in September 2020 Investor Conferences
PALO ALTO, Calif., Sept. 1, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc, (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate in four investor conferences in September:
Eiger will host one-on-one meetings at all conferences. Live webcasts of the Citi panels and Baird and Cantor presentations will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the "Investors" tab. A replay of the webcast will be available approximately one hour following the live event.
Eiger's lead clinical programs target Hepatitis Delta Virus (HDV) infection, the most serious form of human viral hepatitis. Eiger is developing two complementary treatments for HDV. Lonafarnib is a first-in-class, oral prenylation inhibitor in a global Phase 3 trial. Peginterferon lambda is a first-in-class, well-tolerated type III interferon entering Phase 3.
Eiger has filed an NDA and MAA for lonafarnib for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and Progeroid Laminopathies. FDA PDUFA date is November 20, 2020.
For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Investors and Media:
View original content to download multimedia:http://www.prnewswire.com/news-releases/eiger-bio-to-participate-in-september-2020-investor-conferences-301121571.html
SOURCE Eiger BioPharmaceuticals, Inc.
Company Codes: NASDAQ-NMS:EIGR